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a b s t r a c t
We address, for the first time, the impact of skin insertion on multiple occasions of polymeric micronee-
dle arrays in an animal model in vivo. Dissolving microneedle arrays prepared from aqueous blends of
20% w/w Gantrez S-97 BF and 40% w/w poly(vinyl pyrrolidone) 58 kDa and hydrogel-forming micronee-
dle arrays prepared from aqueous blends of and poly(ethyleneglycol) 10 kDa were repeatedly applied to
the skin of hairless mice in vivo. Skin appearance and skin barrier function, as illustrated by measurement
of transepidermal water loss, were not measurably altered during the entire study period. Biomarkers of
infection, immunity and inflammation/irritation were also statistically unchanged, regardless of the
microneedle formulation, needle density or number of applications. Mice remained healthy throughout
and continued to gain weight during the study. For example, transepidermal water loss values were typ-
ically in the range 10–15 g m2 h1 immediately prior to microneedle insertion and 15–25 g m2 h1
immediately following microneedle removal, regardless of when they were measured during the study
periods. Serum biomarker levels, measured immediately post-mortem were always in the range 10–
20 mg ml1 for C-reactive protein, 0.5–1.5 mg ml1 for Immunoglobulin G and 1000–2500 pg ml1 for
interleukin 1-b and were never statistically different from untreated controls. No measurable levels of
tumour necrosis factor-a were found in any animals. These findings are encouraging for the formulations
investigated, suggesting that their repeated use by patients will not cause undesirable side-effects. By
beginning to address potential regulatory questions at an early stage, the microneedles field will be
ideally-placed to take advantage of the potential market. This work illustrates a potential pre-clinical
strategy for development of regulatory dossiers on microneedle technologies.
 2017 The Author. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Microneedle arrays (MN), minimally-invasive devices that pain-
lessly and without drawing blood penetrate the skin’s stratum cor-
neum barrier to greatly expand the range of substances that can be
delivered into and across the skin have shown tremendous pro-
mise over recent years. However, no true MN array-based product
is currently marketed. Indeed, bringing a new drug or a new dosage
form to market is a costly and time-consuming process. Increasing
regional and international regulation, while necessary, has only
served to augment costs [1]. Guidance and regulations established
by the US Food and Drug Administration (FDA) has played a critical
role in providing a framework for many regulatory bodies world-
wide [2,3]. During the development of a new drug or medical
device, an assessment of potential biological risks must be per-
formed. While the possible regulatory questions pertaining to var-
ious MN designs have been speculated upon in the literature [4–7],
only a few relevant experimental studies have been published.
Such investigations, using a mixture of animal models and human
volunteers, recorded changes in skin barrier function through
transepidermal water loss (TEWL) measurements [8,9], local skin
irritation and subcutaneous blood flow [8–11], dimensions of the
induced skin pores [12–14], histological changes and inflammatory
cell infiltrations [12,15].
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Safety studies performed to date have assumed that MN will
always be used for their most commonly suggested application;
as vaccine delivery devices. Accordingly, measurements were
taken after a single MN array insertion. However, our own work
has shown that appropriately-designed MN patches are capable
of delivering therapeutically relevant doses of drugs transdermally,
even when such drugs are not of high potency [16,17]. We have
also illustrated that MN may have a role to play in minimally-
invasive patient monitoring [18,19]. In both of these latter applica-
tions, MN will certainly be inserted into the skin on a regular basis,
with daily use not out of the question. Indeed, even MN vaccines
are likely to be inserted more than once, given the need for prime
and boost regimes to attain strong immunisation for most current
vaccines.
It is our considered view that dissolving polymeric MN arrays
will find their most appropriate use as vaccine delivery vehicles,
due to their ordinarily-limited loading capacity and their tendency
to deposit polymer in skin. As such they will be inserted in skin a
relatively small number of times over a patient’s lifetime. In con-
trast, our hydrogel-forming MN, which swell in skin to allow con-
trolled delivery of a drug substance from an attached patch-type
drug reservoir, or capture skin interstitial fluid for use in patient
monitoring, are removed intact from skin, depositing no measur-
able amount of polymer [16–19]. Since patients may need a drug
administered on a daily basis or routine monitoring for a chronic
condition, these MN are likely to be inserted into skin on a much
more regular basis. Since regulators will undoubtedly ask ques-
tions about the impact of repeated MN insertion, we designed a
series of pre-clinical experiments to investigate this, the results
of which are detailed here.
2. Materials and methods
2.1. Chemicals
Gantrez S-97 BF, a copolymer of methyl-vinyl ether-co-maleic-
acid (PMVE/MA), Mw = 1,500,000 Da) and poly(vinyl pyrrolidone)
(PVP, Mw = 58,000 Da) were provided by Ashland, Surrey, UK. Poly-
ethylene glycol (PEG, Mw = 10,000 Da) was obtained from Sigma-
Aldrich, Steinheim, Germany. Isoflurane was acquired from Abbott
Laboratories, Illinois, USA. Formaldehyde-saline was purchased
from TCS Biosciences Ltd, Buckingham, UK. All other chemicals
used were of analytical reagent grade.
2.2. Animals
Crl: SKH1-Hrhr mice were chosen as the test animals because
they have been previously used as a dermatological animal model
due to their lack of hair [20]. This characteristic avoided the contin-
uous hair removal procedure prior to MN insertion that could
potentially irritate skin. Importantly, unlike other strains of hair-
less mice, Crl: SKH1-Hrhr are immunocompetent [21].
All animal experiments throughout this study were approved
by the Ethics Committee of the QUB Biological Services Unit and
conducted according to the policy of the Federation of European
Laboratory Animal Science Associations (FELASA) and The Euro-
pean Convention for the protection of Vertebrate Animals used
for Experimental and Other Scientific Purposes, with implementa-
tion of the principle of the 3Rs (replacement, reduction, refine-
ment). Any animals with 20% weight loss during the study were
to be removed for euthanasia, but this did not occur. No skin reac-
tions to MN occurred either. At the end of the experiment, eutha-
nasia was by carbon dioxide.
2.3. Biomarker assays
Four biomarkers were measured in mice sera at the end of the
experiment. The biomarkers chosen were: C-reactive protein
(CRP), interleukin 1-b (IL-1b), tumour necrosis factor-a (TNF-a)
and immunoglobulin G (Ig G). CRP levels rapidly increase within
hours after tissue injury or infection, suggesting that it contributes
to host defence and that it is part of the innate immune response
[22]. CRP is a biomarker typically used to diagnose infection and
sepsis [23,24]. CRP serum content was quantified to confirm that
repeated MN skin insertion does not promote skin or systemic
infection. TNF-a is considered the principal mediator of events
involved in inflammation and immunity, playing a preponderant
role in defence against infections by fungi, bacteria and even para-
sites [25]. TNF-a also seems to be a key regulator of local T-cell
proliferation and subsequent development in autoimmune disor-
ders of the skin [26]. IL-1b is one of the key members of the IL-1-
like family of cytokines. This family consists of 11 proteins that
regulate inflammation caused by bacterial or viral infections or in
response to molecular patterns associated with danger and dam-
age. The main producers of IL-1b are cells of the innate immune
system; monocytes and macrophages. Other cell types, however,
such as epithelial cells, astrocytes, and fibroblasts, present in the
skin are also able to express IL-1b [27,28]. Levels of IL-1b have been
connected with inflammatory processes in cancer and skin psoria-
sis [29,30]. Ig G is principally responsible for the recognition, neu-
tralization; and elimination of pathogens and toxic antigens [31].
Ig G is produced in a delayed response to an infection and can be
retained in the body for prolonged periods of time.
Mouse DuoSet ELISA quantification kits for IL-1b, CRP and TNF-
a were purchased from R&D Systems Inc., Minneapolis, USA.
Mouse IgG Total ELISA Ready-SET-Go! was acquired from Affyme-
trix, California, USA. In all cases, appropriate dilutions of samples
were made so as to align with the relevant calibration ranges.
2.4. Microneedles
Laser-engineered silicone micromoulds were manufactured
using a previously detailed method [32]. The features of the nee-
dles produced were conical shapes with: 600 lm heights,
300 lm base widths and 150 lm needle interspacing on a
0.5 cm2 area (19  19 design) and 600 lm heights, 300 lm base
widths and 300 lm needle interspacing a 0.5 cm2 area (11  11
design).
As shown in Fig. 1, hydrogel-forming MN were prepared from
aqueous blends of 15% w/w PMVE/MA and 7.5% w/w PEG as previ-
ously described [16–19]. Dissolving MN were prepared from aque-
ous blends of 20% w/w PMVE/MA and 40% w/w of PVP,
respectively. In each case, formulations were first centrifuged at
3500 rpm for 15 min to ensure a homogenous blend and to remove
any air bubbles. An aliquot of 0.5 g was then cast into the silicone
micromould and centrifuged again at 3500 rpm for a further
15 min. Following air drying, hydrogel-forming MN were cross-
linked by esterification. In all cases, the sidewalls formed during
micromoulding were removed using a heated scalpel prior to use.
2.5. In vivo multiple application of polymeric microneedle arrays
A total number of 36 healthy hairless mice, 18 males and 18
females, were used. Animals were housed according to gender,
polymer, and needle density. There were 12 groups, with three
mice in each group. Two control groups of mice had no MN
inserted into their skin at any time, while the remaining groups
had one of the two densities of either dissolving of hydrogel-
forming MN arrays inserted into their skin repeatedly. Mice always
had the same type of MN inserted and there was no interchanging
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once a mouse was assigned to a particular group. MN were always
applied at the same approximate sites on each mouse. Treated MN
mice were compared with negative control groups (only surgical
tape applied) to verify if any significant changes were observed
in the skin or serum biomarkers.
Dissolving MN arrays were inserted once per week for five con-
secutive weeks in each hairless mouse. In each case, two MN arrays
were inserted into two opposite positions in skin of the lower back
(Fig. 2). MN arrays were inserted by pinching the skin application
site for 30 s with the thumb and forefinger. After MN insertion,
arrays were kept in place for 24 h using surgical tape (MicroporeTM,
3M, Bracknell, UK). The application protocol for hydrogel-forming
MN arrays was the same. However, the frequency of insertion
was increased to twice per week during three successive weeks.
The insertion/application protocols are summarised in Fig. 3.
Mouse well-being was monitored by recording weight once per
week during the performance of the study. Skin appearance was
tracked over time via digital pictures (Nikon CoolpixTM, Nikon,
Tokyo, Japan) taken under controlled lighting conditions. Pho-
tographs of application site were taken before MN patch insertion
Centrifugation:
3,500 rpm
Drying:
48h Room Temp
H2O H2O H2O
Dissolving MNs
Centrifugation:
3,500 rpm
Drying:
48h Room Temp
H2O H2O H2O Crosslinking:
24h 80ºC
Hydrogel-Forming
MNs
A
B
Fig. 1. Diagram A represents dissolving MN array manufacture. Hydrogel-forming MN array manufacture is represented in diagram B.
B
C
A
Fig. 2. MN array skin insertion procedure (A). MN insertion set-up immediately after application with two MN inserted at opposite positions on the lower back of the mouse
(B). Insertion site of a male mouse preceding MN array removal (C).
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and after removal in each case, so as to track any possible skin
changes.
Transepidermal water loss (TEWL) measurements were taken
as a measure of skin barrier function state (VapoMeter, Delfin
Technologies Ltd, Kuopio, Finland). Measurements were taken
directly from the two application sites immediately before each
MN insertion and again immediately following each MN removal.
2.6. Sacrifice, blood collection and biomarker quantification
Mice were euthanised immediately after the last MN array was
removed. Subsequently, blood was collected via cardiac puncture.
To gather serum samples for the ELISAs used to quantify the
biomarkers, Eppendorf tubes were incubated at 37 C for 45 min.
Afterwards, tubes were centrifuged at 4 C at 200 rpm for 15 min.
Supernatant was carefully collected and aliquoted to be stored at
80 C prior to assay by ELISA, following the manufacturers’
instructions and measuring absorbances using an Enspire plater-
eader (Perkin-Elmer, London, UK) at the appropriate wavelengths.
2.7. Statistical analysis
Data was analysed, as appropriate, using the Mann-Whitney
test, Kruskal-Wallis test and Dunns post-test to compare control
group and MN-treated groups. In all cases, p < 0.05 was considered
as a significant difference.
3. Results
3.1. Fabrication of polymeric microneedle arrays and in vivo
application and removal
A total number of 384 MN arrays were produced using the three
formulations and two needle densities. As shown in Fig. 4A and B,
MN arrays had, in each case, fully-formed needles with sharp tips.
As a normal behaviour, mice were inclined to eat the surgical tape
around the abdominal area. However, MN patches were still kept
in place and always remained inserted until removal after 24 h,
as shown in Fig. 5C and D.
A total of 120 dissolving MN arrays were inserted into mouse
skin in vivo over a 5-week period. Upon removal after 24 hours’
insertion, the needles had universally dissolved in skin, leaving
only a gel-like baseplate (Fig. 5A and B). In total, 140 hydrogel-
forming MN patches inserted into mouse skin in vivo over a 3-
3⁰ application2⁰ application1⁰ application 4⁰ application 5⁰ application
Week threeWeek twoWeek one
Remove MN 
patch
Remove MN 
patch
Remove MN 
patch
Remove MN 
patch
Remove MN 
patch
6⁰ application
Remove MN 
patch
3⁰ application2⁰ application1⁰ application 4⁰ application 5⁰ application
Week iveWeek fourWeek threeWeek twoWeek one
Remove MN 
patch
Remove MN 
patch
Remove MN 
patch
Remove MN 
patch
Remove MN 
patch
A
B
Fig. 3. Diagram A describes the dissolving MN array application and removal regime. The hydrogel-forming MN patch application and removal regime is detailed in diagram
B.
BA
Fig. 4. Micrographs exemplify the sharp tips of a 58 kDa PVP 19  19 MN array (A)
and of an 11  11 MN array prepared from Gantrez S-97 (B).
A B
C D
Fig. 5. Dissolving 58 kDa PVP MN arrays dissolved after 24 hours’ skin insertion in
mouse skin in vivo (A) and dissolved Gantrez S-97 MN arrays after 24 hours’ skin
insertion in mouse skin in vivo (B). Hydrogel-forming MN arrays after removal
following 24 hours’ skin insertion in mouse skin in vivo displayed flexibility due to
the uptake of interstitial fluid regardless of whether the needle density used was
11  11 (C) or 19  19 (D).
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week period. All needles remained fully intact when recovered
after 24 hours’ insertion. The hydrogel-forming MN arrays had
swollen in skin and were now flexible in nature (Fig. 5C and D).
3.2. In vivo transdermal water loss measurements, monitoring of skin
appearance and mouse wellbeing
Animal welfare was assessed through the observation of animal
behaviour and monitoring of animal weight. Fig. 6 illustrates the
weight monitoring graphs for the duration of the experiments.
Weights were recorded at the beginning of each week. Each graph
represents a MN array type and a needle density. Additionally,
female and male weight records were plotted separately. It can
observed from the graphs that mouse weight increased over time,
indicating that all animals remained healthy.
Skin appearance was surveyed over the entire duration of the
study. Pictures of the application area were taken before each
and every MN insertion and after each and every MN removal.
Mice were individually identified by ear punch; no ear punch left
ear punch and right ear punch. Mouse identification allowed faith-
ful recording and comparison of skin pictures, TEWL measure-
ments and biomarkers values for each mouse.
In general, immediately after MN removal, all mice displayed
mild erythema at the MN application site. This is most likely due
to MN insertion into skin and surgical tape removal. Indeed, some
control mice showed mild and short-lived erythema around the
site of tape removal. Importantly, erythema had universally and
completely dissipated prior to the next MN insertion in the test
animals. No permanent skin appearance changes were noted for
mice to which dissolving MN were inserted, regardless of MN for-
mulation or density (2 arrays per application per week over a per-
iod of 5 consecutive weeks), as shown in Fig. 7A. The hydrogel-
forming MN-treated group did not show any notable skin alter-
ation, even when MN arrays were inserted twice weekly over
3 weeks. Increased frequency compared to the dissolving MN did
not affect external skin appearance, as Fig. 7B illustrates.
TEWL results are illustrated in Fig. 8. Statistical analyses were
carried out comparing TEWL values for female and male mice. It
was verified that there was no statistical differences between gen-
ders. Therefore, TEWL values were plotted on the same graphs. This
part of the study explored skin barrier function re-establishment
after it had been compromised in a repeated manner using high-
density polymeric MN patches. In each case, TEWL was elevated
immediately following MN removal, but had returned to baseline
prior to the next scheduled MN insertion, with no statistically-
significant trends identified.
3.3. Measurement of inflammation, irritancy and immunological
reaction biomarkers in mouse sera
Encouragingly, TNF-a levels were undetectable in all mice. Data
for the other biomarkers is presented in Fig. 9. No statistical differ-
ences were seen between the measured biomarkers levels com-
pared to one another or control, regardless of formulation type,
needle density, number of applications or mouse gender (p > 0.05
in all cases). These analyses suggest that repeated insertions of dis-
solving or hydrogel-forming MN arrays do not stimulate the
humoral immune system, do not produce sufficient trauma to ele-
vate circulating blood levels of IL-1b and do not caused infection or
trigger an inflammatory response cascade.
4. Discussion
By definition, MN penetrate the skin’s protection stratum cor-
neum barrier and enter the viable epidermis and, in many cases
the dermis. These areas of the body are ordinarily sterile and MN
are not ordinarily manufactured as sterile products. Nevertheless,
only rare and isolated examples of adverse events exist and inap-
propriate use was the cause in the documented cases [7]. MN
insertion typically reduces skin barrier function, as evidenced by
increases in transepidermal water loss and causes local inflamma-
tion and/or irritation to the skin, illustrated by erythema and
oedema [8,15,33–35]. However, these phenomena typically resolve
within a period of several hours, with no long lasting effects
reported [8,15,33–35]. Skin recovery post MN removal is likely to
involve inflammatory and lipid production processes, with prosta-
glandin release [34] and cholesterol synthesis both possibly impor-
tant [36]. High speed application of MN has been shown to cause
localised death of viable cells in skin [37]. This boosts immune
response to delivered vaccine antigens, but is likely to be undesir-
able if the MN are not intended to be used in vaccination, espe-
cially if they are to be inserted in skin regularly. These
phenomena, whilst unlikely to cause prolonged adverse events,
are likely to raise questions from regulatory bodies. In spite of this,
most published work onMN focuses on their design and use, rather
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than specific safety evaluations or regulatory aspects of translation
to clinic. However, it is vitally-important that any questions are
addressed at an early stage, so as not to slow progression to patient
benefit and commercial return.
We expect any approved MN products to be inserted into the
skin of the same patient on more than one occasion, regardless
of the therapeutic indication. Indeed, Zosano Pharma [38] and Cor-
ium [39] have conducted extensive clinical studies, up to comple-
tion of Phase II, where coated titanium and dissolving polymeric
MN, respectively, were repeatedly inserted into the skin of post-
menopausal women over a prolonged period of time for delivery
of parathyroid hormone analogue. No adverse events were
reported, though no data on skin barrier function or serum
biomarkers was published in either case. We believe that it will
be important to show regulators that repeated insertion of MN into
skin does not disturb skin barrier function, or yield any undesirable
systemic effects. This must clearly first be done in an animal
model, prior to human studies and should use non-drug-loaded
MN to illustrate the effect of the MN material, MN density and
number of applications on the measured parameters. Further stud-
ies would then clearly need to be done as a follow-on where drug
(s) to be delivered are included in the formulations.
In the present study, no significant changes to skin appearance
or skin barrier function were observed, regardless of the MN for-
mulation, needle density or number of insertions. Serum biomark-
ers of irritation/inflammation, infection and immunity were not
significantly disturbed by the end of the study periods. These find-
ings are encouraging for the formulations investigated, suggesting
that their repeated use by patients will not cause undesirable side-
effects.
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5. Conclusion
Commercialisation will be the primary route by which patients
will benefit from MN technology. In addressing potential regula-
tory questions at an early stage, the field will be ideally-placed to
take advantage of the potential market. This study addressed, for
the first time, the insertion on multiple occasions of polymeric
MN patches in vivo. This may ultimately reflect the normal pattern
of use of approved MN products. Since skin barrier function was
not compromised during the study and measurement of biomark-
ers of immunity, irritation/inflammation and infection did not raise
any concerns, we are now preparing a follow-on study with human
volunteers using MN manufactured to GMP standards. The out-
comes of such work will allow us to develop a regulatory dossier
to support future applications for marketing approval.
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